摘要
目的探讨早期应用依达拉奉注射液联合康复治疗对急性脑梗死合并肢体功能障碍患者的疗效。方法回顾性分析2009年10月~2011年10月在涿州市医院常规治疗的基础上早期应用依达拉奉注射液联合康复治疗的78例急性脑梗死合并肢体功能障碍患者的临床资料(观察组),并以同期未采用依达拉奉和规范康复治疗的78例患者为对照组,比较两组患者的肢体功能恢复情况。结果观察组患者治疗1个月后上肢Fugl-meyer评分结果为(37.2±11.4)分,下肢为(16.3±6.7)分,对照组分别为(30.1±13.3)分和(14.2±7.2)分,组间比较差异有统计学意义(u=6.679、4.832;P=0.022、0.031)。观察组治疗3个月后上肢Fugl-meyer评分结果为(50.7±8.3)分,下肢为(25.2±4.4)分,对照组分别为(41.6±12.7)分和(20.9±5.3)分,组间比较差异有统计学意义(u=12.467、8.409;P=0、0.016)。观察组患者QOL-35评分结果明显高于对照组,其中观察组QOL-35评分总分为(52±12)分,对照组为(47±13)分,组间比较差异有统计学意义(u=7.509,P=0.004)。结论早期应用依达拉奉注射液联合规范康复治疗有助于患者肢体功能的恢复,可有效提高患者生存质量,值得临床推广。
Objective To investigate the therapeutic efficacy of early application of Edaravone Injection combined with rehabilitation therapy in the treatment of acute cerebral infarction with concurrent limb dysfunction.Methods Retrospective analysis of 78 cases of acute cerebral infarction with limb dysfunction treated with early application of Edaravone Injection and rehabilitation therapy in addition to conventional treatment in Zhuozhou city hospital from October 2009 to October 2011 was performed.78 cases that were not treated with Edaravone and standard rehabilitation were assigned to the control group.Status of limb function recovery of the two groups was compared.Results Fugl-meyer score results of the upper extremity and lower extremity one month after treatment were(37.2±11.4),(16.3±6.7) and(30.1±13.3),(14.2±7.2) scores respectively in the treatment group and control group,showing significant differences(u = 6.679,4.832;P = 0.022,0.031).Fugl-meyer score results of the upper extremity and lower extremity three month after treatment were(50.7±8.3),(25.2±4.4) and(41.6±12.7),(20.9±5.3) scores respectively,showing significant differences(u = 12.467,8.409;P = 0.000,0.016).QOL-35 score was significantly higher in the observation group(52±12) than in the control group(47±13)(u = 7.509,P = 0.004).Conclusion The early application of edaravone injection combined with regulate rehabilitation therapy can help the recovery of limb function,which can effectively improve patients' quality of life,thus it' s worthy of clinical application.
出处
《中国医药导报》
CAS
2012年第14期52-53,56,共3页
China Medical Herald